

In the Claims

1-6 (canceled).

7 (currently amended). A pharmaceutical composition comprising an excipient and a form of a propylene glycol solvate of celecoxib selected from:

- a) a propylene glycol solvate of celecoxib sodium trihydrate characterized by ~~a PXRD pattern~~the PXRD pattern of Figure 19 or Figure 21, said propylene glycol solvate of celecoxib sodium trihydrate having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol: 3 hydrate~~comprising peaks expressed in terms of 2-theta angles, said PXRD pattern comprising:~~
    - i) ~~any 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more peaks selected from peaks at 3.47, 6.97, 10.37, 13.97, 16.41, 19.45, 21.29, 22.69, 23.87 or 25.75 degrees; or~~
    - ii) ~~any 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more peaks at 3.43, 6.95, 10.25, 13.95, 16.39, 17.39, 17.75, 18.21, 19.43, 21.21, 22.61 or 25.71 degrees; or~~
  - b) a propylene glycol solvate of a sodium salt of celecoxib characterized by a PXRD pattern of Figure 2A, 2B, 2C or 2D, said propylene glycol solvate of a sodium salt of celecoxib having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol~~comprising peaks expressed in terms of 2-theta angles, said PXRD pattern comprising any 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the following peaks: 3.77, 7.57, 8.21, 11.33, 14.23, 16.13, 18.69, 20.65, 22.69 and 24.77 degrees;~~
  - e) ~~a propylene glycol solvate of a sodium salt of celecoxib characterized by a PXRD pattern that comprises a peak at 8.21 degrees 2-theta; or~~
  - d) ~~a propylene glycol solvate of a sodium salt of celecoxib characterized by a PXRD pattern that comprises a peak at 8.79 degrees 2-theta~~
- ~~and wherein said PXRD pattern is obtainable by a technique employing a rotating sample tube.~~

8-25 (canceled).

26 (currently amended). The composition according to claim 7, wherein said form is a propylene glycol solvate of celecoxib sodium trihydrate characterized by the PXRD pattern of Figure 19 or Figure 21 and having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol: 3 hydrate~~and the composition is characterized by a PXRD pattern comprising peaks expressed in terms of 2-theta angles, said PXRD pattern comprising any 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more peaks selected from peaks at 3.47, 6.97, 10.37, 13.97, 16.41, 19.45, 21.29, 22.69, 23.87 or 25.75 degrees.~~

27 (currently amended). The composition according to claim 7, wherein said form is a propylene glycol solvate of a sodium salt of celecoxib, said propylene glycol solvate of a sodium salt of celecoxib characterized by a PXRD pattern of Figure 2A, 2B, 2C or 2D and having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol~~and the composition is characterized by a PXRD pattern comprising peaks expressed in terms of 2-theta angles, said PXRD pattern comprising:~~

~~any 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the following peaks: 3.77, 7.57, 8.21, 11.33, 14.23, 16.13, 18.69, 20.65, 22.69 and 24.77 degrees~~

28 (currently amended). The composition according to ~~claim 7~~claim 27, wherein said form is a propylene glycol solvate of a sodium salt of celecoxib and said composition is characterized by the PXRD pattern of Figure 2Aa~~the PXRD pattern that comprises a peak at 8.21 degrees 2-theta.~~

29 (currently amended). The composition according to ~~claim 7~~claim 27, wherein said form is a propylene glycol solvate of a sodium salt of celecoxib and said composition is characterized by the PXRD pattern of Figure 2Ba~~the PXRD pattern that comprises a peak at 8.79 degrees 2-theta.~~

30-31 (canceled).

32 (currently amended). The composition according to ~~claim 7~~claim 27, wherein said form is a propylene glycol solvate of a sodium salt of celecoxib and said composition is characterized by the PXRD pattern of Figure 2C~~said form is a propylene glycol solvate of celecoxib sodium trihydrate and the composition is characterized by a PXRD pattern comprising peaks expressed in terms of 2-theta angles, said PXRD pattern comprising any 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more peaks at 3.43, 6.95, 10.25, 13.95, 16.39, 17.39, 17.75, 18.21, 19.43, 21.21, 22.61 or 25.71 degrees.~~

33 (new). The composition according to claim 26, wherein said form is a propylene glycol solvate of celecoxib sodium trihydrate characterized by the PXRD pattern of Figure 19 and having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol: 3 hydrate.

34 (new). The composition according to claim 26, wherein said form is a propylene glycol solvate of celecoxib sodium trihydrate characterized by the PXRD pattern of Figure 21 and having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol: 3 hydrate.

35 (new). The composition according to claim 27, wherein said form is a propylene glycol solvate of a sodium salt of celecoxib and said composition is characterized by the PXRD pattern of Figure 2D.

36 (new). A propylene glycol solvate of celecoxib selected from:

a) a propylene glycol solvate of celecoxib sodium trihydrate characterized by the PXRD pattern of Figure 19 or Figure 21, said propylene glycol solvate of celecoxib sodium trihydrate having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol: 3 hydrate; or

b) a propylene glycol solvate of a sodium salt of celecoxib characterized by a PXRD pattern of Figure 2A, 2B, 2C or 2D, said propylene glycol solvate of a sodium salt of celecoxib having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol.

37 (new). The propylene glycol solvate according to claim 36, wherein said propylene glycol solvate is a propylene glycol solvate of celecoxib sodium trihydrate characterized by the PXRD pattern of Figure 19 and having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol: 3 hydrate.

38 (new). The propylene glycol solvate according to claim 36, wherein said propylene glycol solvate is a propylene glycol solvate of celecoxib sodium trihydrate characterized by the PXRD pattern of Figure 21 and having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol: 3 hydrate.

39 (new). The propylene glycol solvate according to claim 36, wherein said propylene glycol solvate is a propylene glycol solvate of a sodium salt of celecoxib, said propylene glycol solvate of a sodium salt of celecoxib characterized by a PXRD pattern of Figure 2A, 2B, 2C or 2D and having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol.

40 (new). The propylene glycol solvate according to claim 36, wherein said propylene glycol solvate is a propylene glycol solvate of a sodium salt of celecoxib and said composition is characterized by the PXRD pattern of Figure 2A.

41 (new). The propylene glycol solvate according to claim 36, wherein said propylene glycol solvate is a propylene glycol solvate of a sodium salt of celecoxib and said composition is characterized by the PXRD pattern of Figure 2B.

42 (new). The propylene glycol solvate according to claim 36, wherein said propylene glycol solvate is a propylene glycol solvate of a sodium salt of celecoxib and said composition is characterized by the PXRD pattern of Figure 2C.

43 (new). The propylene glycol solvate according to claim 36, wherein said propylene glycol solvate is a propylene glycol solvate of a sodium salt of celecoxib and said composition is characterized by the PXRD pattern of Figure 2D.

44 (new). A propylene glycol solvate of celecoxib selected from:

a) a propylene glycol solvate of celecoxib sodium trihydrate characterized by a thermogravimetric analysis of Figure 18 or Figure 20, said propylene glycol solvate of celecoxib sodium trihydrate having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol: 3 hydrate; or

b) a propylene glycol solvate of a sodium salt of celecoxib characterized by a thermogravimetric analysis of Figure 1, said propylene glycol solvate of a sodium salt of celecoxib having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol.

45 (new). The propylene glycol solvate of celecoxib according to claim 44, wherein the form is a propylene glycol solvate of celecoxib sodium trihydrate characterized by a thermogravimetric analysis of Figure 18, said propylene glycol solvate of celecoxib sodium trihydrate having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol: 3 hydrate.

46 (new). The propylene glycol solvate of celecoxib according to claim 44, wherein the form is a propylene glycol solvate of celecoxib sodium trihydrate characterized by a thermogravimetric analysis of Figure 20, said propylene glycol solvate of celecoxib sodium trihydrate having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol: 3 hydrate.

47 (new). The propylene glycol solvate of celecoxib according to claim 44, wherein the form is a propylene glycol solvate of a sodium salt of celecoxib characterized by a thermogravimetric analysis of Figure 1, said propylene glycol solvate of a sodium salt of celecoxib having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol.

48 (new). A propylene glycol solvate of celecoxib sodium trihydrate having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol: 3 hydrate.

49 (new). A propylene glycol solvate of a sodium salt of celecoxib having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol.